scholarly journals Major congenital anomalies in babies born with Down syndrome: A EUROCAT population-based registry study

2014 ◽  
Vol 164 (12) ◽  
pp. 2979-2986 ◽  
Author(s):  
Joan K. Morris ◽  
Ester Garne ◽  
Diana Wellesley ◽  
Marie-Claude Addor ◽  
Larraitz Arriola ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Congenital Anomalies ◽  
Population Based ◽  
Registry Study ◽  
Population Based Registry

scholarly journals Epidemiology of multiple congenital anomalies in Europe: A EUROCAT population-based registry study

2014 ◽  
Vol 100 (4) ◽  
pp. 270-276 ◽  
Author(s):  
Elisa Calzolari ◽  
Ingeborg Barisic ◽  
Maria Loane ◽  
Joan Morris ◽  
Diana Wellesley ◽  
...  
Keyword(s):  
Congenital Anomalies ◽  
Population Based ◽  
Registry Study ◽  
Multiple Congenital Anomalies ◽  
Population Based Registry

Neonatal and maternal outcome after blastocyst transfer: a population-based registry study

2016 ◽  
Vol 214 (3) ◽  
pp. 378.e1-378.e10 ◽  
Author(s):  
Erica Ginström Ernstad ◽  
Christina Bergh ◽  
Ali Khatibi ◽  
Karin B.M. Källén ◽  
Göran Westlander ◽  
...  
Keyword(s):  
Population Based ◽  
Maternal Outcome ◽  
Blastocyst Transfer ◽  
Registry Study ◽  
Population Based Registry

scholarly journals The burden and costs of prevention and management of genital disease caused by HPV in women: A population-based registry study in Finland

2013 ◽  
Vol 133 (6) ◽  
pp. 1459-1469 ◽  
Author(s):  
Heini Salo ◽  
Tuija Leino ◽  
Terhi Kilpi ◽  
Kari Auranen ◽  
Petri Tiihonen ◽  
...  
Keyword(s):  
Population Based ◽  
Registry Study ◽  
Population Based Registry ◽  
Genital Disease

Riluzole and other prognostic factors in ALS: a population-based registry study in Italy

2018 ◽  
Vol 265 (4) ◽  
pp. 817-827 ◽  
Author(s):  
Jessica Mandrioli ◽  
◽  
Sara Angela Malerba ◽  
Ettore Beghi ◽  
Nicola Fini ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Population Based ◽  
Registry Study ◽  
Population Based Registry

scholarly journals Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Julio García-Suárez ◽  
◽  
Javier de la Cruz ◽  
Ángel Cedillo ◽  
Pilar Llamas ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cancer Therapy ◽  
Hematologic Malignancy ◽  
Large Population ◽  
Hematologic Malignancies ◽  
Population Based ◽  
Clinical Severity ◽  
Primary Study ◽  
Registry Study ◽  
Population Based Registry

Abstract Background Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. Data on COVID-19 in patients with hematologic malignancies are limited. Here we characterize disease severity and mortality and evaluate potential prognostic factors for mortality. Methods In this population-based registry study, we collected de-identified data on clinical characteristics, treatment and outcomes in adult patients with hematologic malignancies and confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection within the Madrid region of Spain. Our case series included all patients admitted to 22 regional health service hospitals and 5 private healthcare centers between February 28 and May 25, 2020. The primary study outcome was all-cause mortality. We assessed the association between mortality and potential prognostic factors using Cox regression analyses adjusted for age, sex, comorbidities, hematologic malignancy and recent active cancer therapy. Results Of 833 patients reported, 697 were included in the analyses. Median age was 72 years (IQR 60–79), 413 (60%) patients were male and 479 (69%) and 218 (31%) had lymphoid and myeloid malignancies, respectively. Clinical severity of COVID-19 was severe/critical in 429 (62%) patients. At data cutoff, 230 (33%) patients had died. Age ≥ 60 years (hazard ratios 3.17–10.1 vs < 50 years), > 2 comorbidities (1.41 vs ≤ 2), acute myeloid leukemia (2.22 vs non-Hodgkin lymphoma) and active antineoplastic treatment with monoclonal antibodies (2·02) were associated with increased mortality; conventional chemotherapy showed borderline significance (1.50 vs no active therapy). Conversely, Ph-negative myeloproliferative neoplasms (0.33) and active treatment with hypomethylating agents (0.47) were associated with lower mortality. Overall, 574 (82%) patients received antiviral therapy. Mortality with severe/critical COVID-19 was higher with no therapy vs any antiviral combination therapy (2.20). Conclusions In this series of patients with hematologic malignancies and COVID-19, mortality was associated with higher age, more comorbidities, type of hematological malignancy and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk stratification.

scholarly journals A Population-Based Registry Study of Infant Mortality in the Arctic: Greenland and Denmark, 1973–1997

2004 ◽  
Vol 94 (3) ◽  
pp. 452-457 ◽  
Author(s):  
Jeppe Friborg ◽  
Anders Koch ◽  
Flemming Stenz ◽  
Jan Wohlfahrt ◽  
Mads Melbye
Keyword(s):  
Infant Mortality ◽  
Population Based ◽  
The Arctic ◽  
Registry Study ◽  
Population Based Registry
Sign in / Sign up

Export Citation Format

Share Document